Israel Englander’s BridgeBio Oncology BBOT Stock Holding History

Israel Englander’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$804K	Sell	105,480 -160,474	-60%	-$1.34M	﹤0.01%	4466
2026 Q1	$2.38M	Buy	265,954 +24,539	+10%	+$263K	﹤0.01%	3707
2025 Q4	$3.02M	Sell	241,415 -128,148	-35%	-$1.55M	﹤0.01%	3546
2025 Q3	$4.06M	Sell	369,563 -527,688	-59%	-$5.5M	﹤0.01%	3355
2025 Q2	$9.53M	Sell	897,251 -199,131	-18%	-$2.15M	﹤0.01%	2310
2025 Q1	$12.4M	Sell	1,096,382 -45,920	-4%	-$494K	0.01%	1963
2024 Q4	$12M	Buy	1,142,302 +11,985	+1%	+$126K	0.01%	2000
2024 Q3	$11.8M	Buy	1,130,317 +12,917	+1%	+$134K	0.01%	2037
2024 Q2	$11.4M	Buy	1,117,400 +11,610	+1%	+$119K	0.01%	1972
2024 Q1	$11.5M	Buy	+1,105,790	New	+$11.4M	﹤0.01%	2050

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Israel Englander's BBOT Position: Q2 2026 in Review

Israel Englander reduced its BridgeBio Oncology (BBOT) stake by 60% in Q2 2026, selling an estimated $1.34M and leaving 105,480 shares worth $804K. The position accounts for ﹤0.01% of the portfolio, ranked #4466.

Israel Englander first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.4M in Q1 2025. 66 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

Israel Englander held 105,480 shares of BridgeBio Oncology worth $804K as of Q2 2026.
Israel Englander sold 160,474 BridgeBio Oncology shares in Q2 2026, an estimated $1.34M.
BridgeBio Oncology made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4466 holding.
Israel Englander first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
Israel Englander's BridgeBio Oncology position peaked at $12.4M in Q1 2025.
66 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.